Physician profile
Mabel Ng
NPI 1154679546
$15,881.22
in general payments reported to CMS, 2019-2025
34 companies · $2,937 in 2025
The $2,937 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,167 · 2022: $3,793 · 2023: $2,808 · 2024: $3,176 · 2025: $2,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,822 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,821.83 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,105.19 | 2021-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $2,566.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,718.97 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,357.15 | 2021-2025 | Benlysta |
| Janssen Biotech, INC. | $1,164.96 | 2021-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $797.75 | 2021-2025 | Saphnelo |
| Ucb, INC. | $748.36 | 2021-2025 | Bimzelx, Cimzia |
| Alexion Pharmaceuticals, INC. | $605.94 | 2022-2025 | Strensiq, Ultomiris |
| Mallinckrodt Hospital Products INC. | $552.21 | 2021-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $540.98 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $431.79 | 2021-2025 | Orencia |
| Lilly USA, LLC | $420.54 | 2021-2023 | Taltz |
| Radius Health, INC. | $359.53 | 2022-2025 | Tymlos |
| Pfizer INC. | $339.77 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $180.16 | 2023-2025 | Idacio, Tyenne, Adalimumab-Aacf |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $134.38 | 2022-2024 | Monovisc |
| Horizon Therapeutics Plc | $110.07 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $99.59 | 2022-2023 | Seglentis |
| Ani Pharmaceuticals, INC. | $98.83 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Hikma Pharmaceuticals USA | $98.51 | 2021-2023 | Mitigare |
| Kiniksa Pharmaceuticals International, Plc | $71.26 | 2024 | Arcalyst |
| Sobi, INC | $53.46 | 2022-2024 | |
| Genentech USA, INC. | $52.81 | 2023-2024 | Actemra |
| Scilex Pharmaceuticals INC. | $48.81 | 2024-2025 | |
| Bioventus LLC | $35.41 | 2022-2024 | Durolane |
| Kiniksa Pharmaceuticals, LTD. | $25.00 | 2023 | Arcalyst |
| Argenx US, INC. | $24.77 | 2022 | |
| Zimmer Biomet Holdings, INC. | $24.04 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Tonix Medicines, INC. | $23.44 | 2025 | Tonmya |
| Octapharma USA, INC. | $22.76 | 2024 | Octagam Immune Globulin (Human) |
| Genzyme Corporation | $19.90 | 2021 | |
| Shorla Oncology INC. | $17.42 | 2024 | |
| Eyevance Pharmaceuticals LLC | $15.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.66 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mabel Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.